This clinical trial is focused on studying Type 1 Diabetes, a condition where the body’s immune system attacks the cells in the pancreas that produce insulin. The study aims to evaluate the safety and effectiveness of a treatment called Diamyd, which is a suspension for injection containing a substance known as glutamate decarboxylase 2, human, recombinant. This treatment is being tested to see if it can help preserve the function of the insulin-producing cells in people who have recently been diagnosed with Type 1 Diabetes and carry a specific genetic marker known as the HLA DR3-DQ2 haplotype. Some participants in the study may receive a placebo instead of the actual treatment.

The study will involve participants receiving three doses of Diamyd over a period of time, with the goal of assessing its impact on the body’s ability to produce insulin and maintain blood sugar levels. Participants will be monitored for changes in their insulin production and blood sugar control over the course of the study. The study will also look at the safety of the treatment by tracking any side effects or reactions that occur during the trial.

In addition to Diamyd, the study will also involve the use of Divisun 2000 IE tabletter, which contains colecalciferol, commonly known as Vitamin D3. This is a vitamin supplement taken orally in tablet form. The study will last for a period of up to 24 months, during which participants will undergo regular assessments to monitor their health and the effects of the treatment. The overall aim is to determine if Diamyd can help preserve the body’s natural insulin production in people with newly diagnosed Type 1 Diabetes.